Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of OZURDEX 700 μg intravitreal implant in applicator is substantial. |
Clinical Added Value
| minor |
OZURDEX 700 μg intravitreal implant in applicator offers a minor improvement in actual benefit (IAB IV) in the management of the treatment of macular oedema and oedema following either branch retinal vein occlusion or central retinal vein occlusion. |
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
EqRtudQDMNn7wkkn
